Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 27, 2025 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics stock potentially impacted by class action lawsuit alleging securities fraud and company's decision to halt NTLA-3001 research program.
The lawsuit and program discontinuation directly impact Intellia's stock, signaling potential financial and operational challenges that could negatively affect investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100